Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuxuening Injection with IV Thrombolysis in Acute Ischemic Stroke
NCT06157502Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Shuxuening Injection with Placebo (2 arms). Primary endpoint: Proportion of mRS score 0 to 1 at 90 days. Started Jan 2024; status: recruiting.
02
Drugs
ginkgo biloba leaf extract injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06157502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157502.